Skip to main content
Top
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Pseudomonas Aeruginosa | Research

Processed human amniotic fluid retains its antibacterial activity

Authors: Yong Mao, Jan Pierce, Anya Singh-Varma, Michael Boyer, Joachim Kohn, Jo-Anna Reems

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Background

Human amniotic fluid (AF) contains numerous nutrients, trophic factors and defense proteins that provide a nurturing and protective environment for fetal development. Based on reports that AF has antibacterial, anti-inflammatory and regenerative properties, we designed a novel method to process AF for use in clinical care.

Methods

Six randomly selected lots of processed AF (pAF) were examined to determine whether they retained their antibacterial activity against a panel of wound-associated pathogens E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. aerogenes (ESKAPE). To identify proteins in pAF that might be responsible for its antibacterial activity, three different lots of pAF were analyzed with quantitative cytokine arrays that consisted of 400 unique human proteins. One protein identified by microarrays, lactoferrin, and a second prominent antibacterial protein that was not identified by microarrays, lysozyme, were examined by depletion experiments to determine their contribution to the antibacterial activity of pAF.

Results

All six lots of pAF exhibited antibacterial activity against ESKAPE microorganisms, especially against the pathogens predominately found in chronic wounds (i.e. S. aureus and P. aeruginosa). Thirty-one of the peptides on the microarray were annotated as having antibacterial activity and 26 of these were detected in pAF. Cystatin C and lactoferrin were among the most highly expressed antibacterial proteins in pAF. Cystatin C and lactoferrin were confirmed by ELISA to be present in pAF along with lysozyme. Immunoprecipitation of lactoferrin and lysozyme reduced, but did not abolish the antibacterial activities of pAF.

Conclusion

Our data demonstrate that pAF maintains antibacterial activity via the preservation of antibacterial proteins against a broad spectrum of wound-associated pathogens.
Literature
1.
go back to reference Silini AR, et al. The long path of human placenta, and its derivatives, in regenerative medicine. Front Bioeng Biotechnol. 2015;3:162.CrossRef Silini AR, et al. The long path of human placenta, and its derivatives, in regenerative medicine. Front Bioeng Biotechnol. 2015;3:162.CrossRef
2.
go back to reference Tyszkiewicz JT, et al. Amnion allografts prepared in the central tissue bank in Warsaw. Ann Transplant. 1999;4(3–4):85–90.PubMed Tyszkiewicz JT, et al. Amnion allografts prepared in the central tissue bank in Warsaw. Ann Transplant. 1999;4(3–4):85–90.PubMed
3.
go back to reference Stock SJ, et al. Natural antimicrobial production by the amnion. Am J Obstet Gynecol. 2007;196(3):255.CrossRef Stock SJ, et al. Natural antimicrobial production by the amnion. Am J Obstet Gynecol. 2007;196(3):255.CrossRef
4.
go back to reference Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–8.CrossRef Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–8.CrossRef
5.
go back to reference Bergman N, Bercovici B, Sacks T. Antibacterial activity of human amniotic fluid. Am J Obstet Gynecol. 1972;114(4):520–3.CrossRef Bergman N, Bercovici B, Sacks T. Antibacterial activity of human amniotic fluid. Am J Obstet Gynecol. 1972;114(4):520–3.CrossRef
6.
go back to reference Cattaneo P. Potere Lisimico del liquido amniotico postere antilizimico del meconoio richerche superimentoli. Clin Obstet Gynaecol. 1949;51:60. Cattaneo P. Potere Lisimico del liquido amniotico postere antilizimico del meconoio richerche superimentoli. Clin Obstet Gynaecol. 1949;51:60.
7.
go back to reference Ojo VA, Okpere EE, Obaseiki-Ebor EE. Antimicrobial properties of amniotic fluid from some Nigerian women. Int J Gynaecol Obstet. 1986;24(2):97–101.CrossRef Ojo VA, Okpere EE, Obaseiki-Ebor EE. Antimicrobial properties of amniotic fluid from some Nigerian women. Int J Gynaecol Obstet. 1986;24(2):97–101.CrossRef
8.
go back to reference Akinbi HT, et al. Host defense proteins in vernix caseosa and amniotic fluid. Am J Obstet Gynecol. 2004;191(6):2090–6.CrossRef Akinbi HT, et al. Host defense proteins in vernix caseosa and amniotic fluid. Am J Obstet Gynecol. 2004;191(6):2090–6.CrossRef
9.
go back to reference Mussap M, et al. Predictive value of amniotic fluid cystatin C levels for the early identification of fetuses with obstructive uropathies. BJOG. 2002;109(7):778–83.CrossRef Mussap M, et al. Predictive value of amniotic fluid cystatin C levels for the early identification of fetuses with obstructive uropathies. BJOG. 2002;109(7):778–83.CrossRef
10.
go back to reference Ammons MC, Copie V. Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling. 2013;29(4):443–55.CrossRef Ammons MC, Copie V. Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling. 2013;29(4):443–55.CrossRef
11.
go back to reference Jasir A, et al. New antimicrobial cystatin C-based peptide active against Gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci. APMIS. 2003;111(11):1004–10.CrossRef Jasir A, et al. New antimicrobial cystatin C-based peptide active against Gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci. APMIS. 2003;111(11):1004–10.CrossRef
12.
go back to reference Thadepalli H, Gangopadhyay PK, Maidman JE. Amniotic fluid analysis for antimicrobial factors. Int J Gynaecol Obstet. 1982;20(1):65–72.CrossRef Thadepalli H, Gangopadhyay PK, Maidman JE. Amniotic fluid analysis for antimicrobial factors. Int J Gynaecol Obstet. 1982;20(1):65–72.CrossRef
13.
go back to reference Schlievert P, Johnson W, Galask RP. Bacterial growth inhibition by amniotic fluid. V. Phosphate-to-zinc ratio as a predictor of bacterial growth-inhibitory activity. Am J Obstet Gynecol. 1976;125(7):899–905.CrossRef Schlievert P, Johnson W, Galask RP. Bacterial growth inhibition by amniotic fluid. V. Phosphate-to-zinc ratio as a predictor of bacterial growth-inhibitory activity. Am J Obstet Gynecol. 1976;125(7):899–905.CrossRef
14.
go back to reference Ismail MA, Salti GI, Moawad AH. Effect of amniotic fluid on bacterial recovery and growth: clinical implications. Obstet Gynecol Surv. 1989;44(8):571–7.CrossRef Ismail MA, Salti GI, Moawad AH. Effect of amniotic fluid on bacterial recovery and growth: clinical implications. Obstet Gynecol Surv. 1989;44(8):571–7.CrossRef
15.
16.
go back to reference Pierce J, et al. Collection and characterization of amniotic fluid from scheduled C-section deliveries. Cell Tissue Bank. 2016;17(3):413–25.CrossRef Pierce J, et al. Collection and characterization of amniotic fluid from scheduled C-section deliveries. Cell Tissue Bank. 2016;17(3):413–25.CrossRef
17.
go back to reference Leaper D, Assadian O, Edmiston CE. Approach to chronic wound infections. Br J Dermatol. 2015;173(2):351–8.CrossRef Leaper D, Assadian O, Edmiston CE. Approach to chronic wound infections. Br J Dermatol. 2015;173(2):351–8.CrossRef
18.
go back to reference Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–22.CrossRef Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–22.CrossRef
19.
go back to reference Snyder RJ, et al. Wound biofilm: current perspectives and strategies on biofilm disruption and treatments. Wounds. 2017;29(6):S1–17.PubMed Snyder RJ, et al. Wound biofilm: current perspectives and strategies on biofilm disruption and treatments. Wounds. 2017;29(6):S1–17.PubMed
20.
go back to reference Zhao R, et al. Inflammation in chronic wounds. Int J Mol Sci. 2016;17(12):2085.CrossRef Zhao R, et al. Inflammation in chronic wounds. Int J Mol Sci. 2016;17(12):2085.CrossRef
21.
go back to reference Mao Y, Hoffman T, Johnson A, Duan-Arnold Y, Danikovitch A, Kohn J. Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds. J Diab Foot Compl. 2016;8(2):23–30. Mao Y, Hoffman T, Johnson A, Duan-Arnold Y, Danikovitch A, Kohn J. Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds. J Diab Foot Compl. 2016;8(2):23–30.
22.
go back to reference Mao Y, et al. Antimicrobial peptides secreted from human cryopreserved viable amniotic membrane contribute to its antibacterial activity. Sci Rep. 2017;7(1):13722.CrossRef Mao Y, et al. Antimicrobial peptides secreted from human cryopreserved viable amniotic membrane contribute to its antibacterial activity. Sci Rep. 2017;7(1):13722.CrossRef
23.
go back to reference Hicks RP, et al. Antimicrobial peptides containing unnatural amino acid exhibit potent bactericidal activity against ESKAPE pathogens. Bioorg Med Chem. 2013;21(1):205–14.CrossRef Hicks RP, et al. Antimicrobial peptides containing unnatural amino acid exhibit potent bactericidal activity against ESKAPE pathogens. Bioorg Med Chem. 2013;21(1):205–14.CrossRef
24.
25.
go back to reference Loukogeorgakis SP, De Coppi P. Concise review: amniotic fluid stem cells: the known, the unknown, and potential regenerative medicine applications. Stem Cells. 2017;35(7):1663–73.CrossRef Loukogeorgakis SP, De Coppi P. Concise review: amniotic fluid stem cells: the known, the unknown, and potential regenerative medicine applications. Stem Cells. 2017;35(7):1663–73.CrossRef
26.
go back to reference Yoon BS, et al. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev. 2010;19(6):887–902.CrossRef Yoon BS, et al. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev. 2010;19(6):887–902.CrossRef
27.
go back to reference Brzin J, et al. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun. 1984;118(1):103–9.CrossRef Brzin J, et al. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun. 1984;118(1):103–9.CrossRef
28.
go back to reference Wittek N, Majewska E. Cystatin C—modulator of immune processes. Przegl Lek. 2010;67(7):484–7.PubMed Wittek N, Majewska E. Cystatin C—modulator of immune processes. Przegl Lek. 2010;67(7):484–7.PubMed
29.
go back to reference Leung-Tack J, et al. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14(3):247–58.CrossRef Leung-Tack J, et al. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14(3):247–58.CrossRef
30.
go back to reference Leung-Tack J, et al. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res. 1990;188(1):16–22.CrossRef Leung-Tack J, et al. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res. 1990;188(1):16–22.CrossRef
31.
go back to reference Liao Y, et al. Proteomic characterization of human milk whey proteins during a twelve-month lactation period. J Proteome Res. 2011;10(4):1746–54.CrossRef Liao Y, et al. Proteomic characterization of human milk whey proteins during a twelve-month lactation period. J Proteome Res. 2011;10(4):1746–54.CrossRef
32.
go back to reference Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. 2005;62(22):2576–87.CrossRef Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. 2005;62(22):2576–87.CrossRef
33.
go back to reference Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie. 2009;91(1):11–8.CrossRef Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie. 2009;91(1):11–8.CrossRef
34.
go back to reference Puddu P, et al. Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS ONE. 2011;6(7):e22504.CrossRef Puddu P, et al. Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS ONE. 2011;6(7):e22504.CrossRef
35.
go back to reference Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005;78(1):14–26.CrossRef Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005;78(1):14–26.CrossRef
36.
go back to reference Detmers PA, et al. Differential effects of neutrophil-activating peptide 1/IL-8 and its homologues on leukocyte adhesion and phagocytosis. J Immunol. 1991;147(12):4211–7.PubMed Detmers PA, et al. Differential effects of neutrophil-activating peptide 1/IL-8 and its homologues on leukocyte adhesion and phagocytosis. J Immunol. 1991;147(12):4211–7.PubMed
37.
go back to reference Aguila A, et al. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunol Med Microbiol. 2001;31(2):145–52.CrossRef Aguila A, et al. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunol Med Microbiol. 2001;31(2):145–52.CrossRef
38.
go back to reference Shimada T, et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe. 2010;7(1):38–49.CrossRef Shimada T, et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe. 2010;7(1):38–49.CrossRef
Metadata
Title
Processed human amniotic fluid retains its antibacterial activity
Authors
Yong Mao
Jan Pierce
Anya Singh-Varma
Michael Boyer
Joachim Kohn
Jo-Anna Reems
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1812-8

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue